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OBJECTIVES: Determine if Medicare Part D beneficiaries who received telephone
MTM services had:1) Decreased medication/health-related problems (MHRPs); 2)
Improved medication adherence; and 3) Decreased total Part D drug costs when
compared to a control group. METHODS: Part D beneficiaries from a Texas health
plan participated. The Andersen Model was the theoretical framework. Indepen-
dent variables were: predisposing factors (age, gender, and race); and need factors
(number of medications and chronic diseases andmedication regimen complexity
(MRC). The health behavior (intervention) was MTM utilization. Outcomes were
change (from baseline to 12-month follow-up) in: 1) Number of MHRPs; 2) Medica-
tion adherence measured by the medication possession ratio (MPR); and 3) Total
drug costs. Descriptive and inferential statistical analyses were conducted.
RESULTS: The intervention (n60) and control (n60) groups were not statistically
different regarding age (71.27.5 vs.73.98.0), medications (13.03.2 vs.13.23.4),
chronic diseases (6.52.3 vs.7.02.1) or MRC [(21.5 (range 8–43) vs.22.8 (range
9–42.5)], respectively. The majority (51%) were male in the intervention group but
only 28% were male in the control group (p0.009). At baseline, 4.8 2.7 (interven-
tion group) and 9.1 2.9 (control group) MHRPs were identified and 2.22.0 and
7.33.0 MHRPs remained at the 12-month follow-up, respectively. Multivariate
regression revealed that MHRPs decreased significantly (p0.0120) among the in-
tervention group when compared to the control group. There were no significant
predictors of change in MPR. Total drug costs (change from baseline to follow-up)
decreased by $588$2,086 in the intervention group and increased by $207$1,752
in the control group. A t-test indicated the cost difference between the 2 groupswas
significant (p0.03), but the multivariate regression did not indicate significant
predictors.CONCLUSIONS:A telephoneMTMprogrampositively impactedMHRPs.
Unadjusted cost comparisons also showed cost savings among the intervention
group. Future research should focus on understanding predictors that impact ad-
herence and cost-related MTM outcomes.
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IMPACT OF MONTHLY PRESCRIPTION CAP ON MEDICATION PERSISTENCY
AMONG PATIENTS WITH DIABETES, HYPERTENSION, OR HYPERLIPIDEMIA
Wang CC, Wei D, Farley J
University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
OBJECTIVES: To evaluate the effect of a policy implemented in the Louisiana Med-
icaid programwhich capped reimbursement to eight prescriptions permember per
month on medication persistency in patients with diabetes, hypertension, or
hyperlipidemia. METHODS: A pre-post non-equivalent comparator group design
was applied using Medicaid claims data from 2001-2003 for Louisiana (LA) and
Indiana (IN) to identify patients with the specified conditions and their medication
persistency. Persistency was defined as the number of days to discontinuation
which was identified as a gap in treatment 30 days or longer. To capture pre-
intervention trends in medication persistency, we compared “pre-policy” cohorts
in LA and IN followed for ten months prior to policy adoption (March 3, 2002 to
December 31, 2002) to policy cohorts followed ten months after policy adoption
(March 3, 2003 to December 31, 2003). All incident cohorts were identified using a
six-monthwashout period.We used Cox-proportional hazardmodels to compared
discontinuation rates in LA and IN across the pre-policy and policy period cohorts.
RESULTS: After adjusting for patient characteristics and comorbid conditions, no
significant differences in persistency were found prior to policy implementation
between LA and IN for any of the three chronic conditions. In the post-policy
period, all cohorts had significantly lower persistency in LA than in IN. Patients in
LA with diabetes and hypertension were 1.38 (p 0.03) and 2.00 (p0.01) times
more likely to discontinue their medications at day 30 of the follow-up, respec-
tively. The hazard ratios declined to 1.21 and 1.67 for diabetes and hypertension
patients respectively after 260 days. The hazard ratio of discontinuation for pa-
tients with hyperlipidemia in LA was constantly 1.31 (p0.01) across the follow-up
period. CONCLUSIONS: Patients with chronic conditions subject to medication
capsmay be vulnerable to medication discontinuation. Policy makers need to con-
sider carefully when implementing such policies on patients with chronic condi-
tions.
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EVALUATION OF CLINICAL LABORATORY-PHARMACY LINKAGE DECISION
SUPPORT IN THE USE OF POTASSIUM SUPPLEMENTS
Yu S, Galanter W, Lin FJ, Lambert B
University of Illinois at Chicago, Chicago, IL, USA
OBJECTIVES: Clinical decision support (CDS) has been utilized to link laboratory
and pharmacy data to optimize medication therapy. This study aimed to evaluate
the effect of synchronous and asynchronousCDS in inpatients receiving potassium
supplements.METHODS: The synchronous and real-time asynchronous lab-phar-
macy CDS was implemented in our 450-bed academic teaching hospital in June
2003. Non-hemolyzed serum potassium ([K]) values and medication orders for
potassium supplements, 12 months prior to and after CDS implementation, were
analyzed. A Cox proportional hazardsmodelwas constructed to assess the effect of
CDS in improving clinicians’ response time at the presence of hyperkalemia. Po-
tassium5.0 mEq/L and5.4 mEq/L were used to define high normal and elevated
hyperkalemia. Response time was measured from the time of the first instance of
hyperkalemia to cancelation of themedication order. Response timewas censored
at the time of a consequent normal potassium or patient discharge. RESULTS: In
the pre-CDS period, 12.5% (1439/11512) of the potassium supplement orders were
followed by at least one abnormal serumpotassiumvalue;whereas in the post-CDS
period, 10.96% (1206/11005) of the orders were alerted by CDS.While controlling for
patient characteristics, posting time of the hyperkalemic results, and severity of
hyperkalemia (5.0mEq/L[K]5.4mEq/L vs. [K]5.4mEq/L), potassium supple-
ment orders were cancelled more rapidly after CDS implementation (hazard ra-
tio[HR]1.14, p0.007). Moreover, clinicians responded sooner if the result with
hyperkalemia was posted during 6am-noon vs. midnight-6am (HR1.36, p0.001),
while the response time was longer if the result was posted during noon-6pm
(HR0.73, p0.004) or 6pm-Midnight (HR0.57, p0.001). Patient age, sex, race, and
the severity of hyperkalemia had no significant effect on clinicians’ response time.
CONCLUSIONS: The synchronous and asynchronous real-time lab-pharmacy link-
age decision support helped clinicians to manage potassium supplements in a
more timely manner in patients with high normal or elevated potassium.
PODIUM SESSION I:
EMPLOYEE HEALTH & PRODUCTIVITY OUTCOMES RESEARCH
OR1
THE ASSOCIATION BETWEEN SELF-PERCEIVED COGNITIVE DIFFICULTIES AND
LEVEL OF DEPRESSION AMONG EMPLOYEES WITH CURRENT DEPRESSION
Lawrence C1, Roy A2, Harikrishnan V2, Yu S2, Dabbous OH2
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OBJECTIVES:Many facets of job performance may be impaired by depression. Im-
paired performance by depressed employees may be attributed to self-perceived
cognitive difficulties. The goal of the current study was to assess self-perceived
deficits in cognition experienced by employees with depression. METHODS: Indi-
viduals (18 years of age) employed full-time with diagnosed depression (exclud-
ing bipolar disorder) completed a Web-based computer-generated 25-minute sur-
vey in February 2010 (study population identified by Harris InteractiveTM). The
patient survey used the Perceived Deficits Questionnaire (PDQ) to assess self-per-
ceived difficulties in memory, attention, planning and organization, and concen-
tration using a 0-20 scale, where higher scores indicate greater impairment. The
Patient Health Questionnaire (PHQ-9) was used to assess depression severity. The
impact of depression on the PDQ scoreswas assessed using a trend test based on an
analysis of covariancewith age, gender, and PHQ-9 score as independent variables.
RESULTS: A total of 1051 employees were included in the analysis (58% female,
mean age 47 yrs, and 38% held professional employment). PHQ-9 scores indicated
423 (40.25%) employees with no depression symptoms, 319 (30.35%) with mild de-
pression, 166 (15.79%) with moderate depression, 82 (7.80%) with moderately se-
vere depression, and 61 (5.80%) with severe depression. PDQ scores showed that
perceived cognitive functioningworsened progressivelywith increasing severity of
depression symptoms (p0.0001). PDQ scores showed the most impairment in the
attention/concentration and planning/organization scales in the severely de-
pressed (12.26 and 12.25, respectively) comparedwith non-depressed subjects (4.45
and 3.75, respectively). CONCLUSIONS: In full-time employees experiencing de-
pression, self-perceived cognitive difficulties worsened with increasing severity of
depressive symptoms.
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ASSESSING THE RELATIONSHIP BETWEEN MEDICATION ADHERENCE AND
EMPLOYEE PRODUCTIVITY
Loeppke R1, Haufle V2, Jinnett K3
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Benefits Institute, San Francisco, CA, USA
OBJECTIVES: This study examined how adherence to prescribed medications for
specific chronic conditions affects lostwork time and on-the-job performance in an
employed population. METHODS: Patients aged 18 to 64, with at least one of four
conditions – CAD, hypertension, Type II diabetes, or depression – were identified
from claims data for employees of five employers. Patients had also completed a
health and productivity assessment (HPA). We conducted descriptive and regres-
sion analyses of the merged claims (12-months pre-HPA) and HPA data to assess
whether medication adherence, comorbidity, health risks and other factors were
associatedwithworkplace productivity. Adherencemeasures includedMedication
Possession Ratio (MPR) and a dichotomous measure that assigned “adherent” pa-
tients with anMPR greater than 80%. RESULTS: The study population showed high
rates of adherence: mean MPR ranged from 0.70 to 0.79 across conditions. Better
adherencewas associatedwith fewer lost hours due to absence for CADpatients on
statin therapy and diabetes patients on statin or ACE/ARB therapy. For Diabetes
patients on insulin or like treatment, those with MPRs of 0.80 or higher had higher
job performance and fewer total work hours missed than individuals with MPRs
lower than 0.80. Unexpectedly, better adherence by CAD patients on anti-platelet
therapy was associated with poorer on-the-job performance. The presence of co-
morbid diseases and higher health risk status was associated with increased ab-
sence and poorer job performance across the four conditions. Those in the profes-
sional/executive job class typically had less absence from work but lower job
performance. CONCLUSIONS: Despite high rates of adherence in this population,
significant medication treatment effects were observed, as were consistent effects
of comorbidities, health risks and job class on lost work time. Better targeting of
treatment by job class for individualswith high health risks and comorbiditiesmay
help reduce health risks and improve productivity outcomes.
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